Last ¥1,445 JPY
Change Today +1.00 / 0.07%
Volume 1.2M
4151 On Other Exchanges
Symbol
Exchange
Munich
OTC US
As of 1:00 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

kyowa hakko kirin co ltd (4151) Snapshot

Open
¥1,455
Previous Close
¥1,444
Day High
¥1,455
Day Low
¥1,440
52 Week High
07/31/14 - ¥1,510
52 Week Low
03/20/14 - ¥1,006
Market Cap
833.0B
Average Volume 10 Days
1.1M
EPS TTM
¥29.05
Shares Outstanding
576.5M
EX-Date
06/26/15
P/E TM
49.7x
Dividend
¥25.00
Dividend Yield
1.73%
Current Stock Chart for KYOWA HAKKO KIRIN CO LTD (4151)

Related News

No related news articles were found.

kyowa hakko kirin co ltd (4151) Related Businessweek News

No Related Businessweek News Found

kyowa hakko kirin co ltd (4151) Details

Kyowa Hakko Kirin Co., Ltd. manufactures and markets pharmaceuticals and bio-chemicals primarily in Asia, Europe, and the United States. The company’s Pharmaceuticals segment researches, develops, produces, and sells ethical drugs for the treatment of various diseases, including renal anemia, oncology, allergies, and hypertension. Its principal ethical drugs include NESP/ESPO, an ESA formulation; REGPARA, a secondary hyperparathyroidism; CONIEL, a hypertension and angina pectoris; ONGLYZA, a treatment for type 2 diabetes; GRAN, a G-CSF agent; Fentos, a transdermal product; POTELIGEO, an adult T-cell leukemia-lymphoma; Romiplate, a chronic idiopathic thrombocytopenic purpur; ALLELOCK, an antiallergic agent; Patanol antiallergic eye drops; ASACOL, an ulcerative colitis treatment; NOURIAST, an antiparkinsonian agent; and DEPAKENE, an antiepileptic agent. This segment also offers in vitro diagnostic reagents, such as POTELIGEO tests and Determiner clinical chemistry diagnostic reagents. The company’s Bio-chemicals segment produces and sells amino acids, nucleotides, and related compounds for use in pharmaceuticals and their intermediates, health foods, dietary supplements, and cosmetics. This segment also produces plant growth regulators; designs and installs plant facilities and equipment; manufactures active pharmaceutical ingredients, pharmaceutical intermediates, industrial raw materials, and health care products; sale of fine chemicals; and is involved in mail-order sale of healthcare products in Japan. In addition, the company is engaged in pharmaceuticals licensing, as well as insurance, wholesale, and retail activities. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Founded in 1949

kyowa hakko kirin co ltd (4151) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kyowa hakko kirin co ltd (4151) Key Developments

Kyowa Hakko Kirin Co., Ltd. Announces Consolidated Financial Results for the Fourth Quarter and Consolidated and Non Consolidated Financial Results for the Year Ended December 31, 2014; Provides Earnings Guidance for the Six Months Ending June 2015 and Year Ending December 31, 2015

Kyowa Hakko Kirin Co., Ltd. announced consolidated and non-consolidated financial results for the fourth quarter and year ended December 31, 2014. For the year, the company reported on consolidated basis net sales of ¥333.4 billion against ¥340.6 billion a year ago. Operating income (prior to amortization of goodwill) was ¥45.4 billion against ¥61 billion a year ago. Operating income was ¥36.1 billion against ¥51.7 billion a year ago. Ordinary income was ¥29.5 billion against ¥49.5 billion a year ago. Income before income taxes and minority interests was ¥27.2 billion against ¥49.7 billion a year ago. Net income was ¥15.8 billion against ¥30 billion a year ago. EPS prior to amortization of goodwill of ¥45.95 against ¥71.85 a year ago. Capital expenditure was ¥27.2 billion against ¥24.8 billion a year ago. Cash flows from operating activities was ¥19.3 billion against ¥56.8 billion a year ago. Return on equity was 2.7% against 5.2% a year ago. Fully diluted net income per share was ¥29.02 against ¥54.91 a year ago. For the year, the company reported non-consolidated basis net sales of ¥201.791 billion against ¥210.934 billion a year ago. Operating income was ¥35.050 billion against ¥49.903 billion a year ago. Ordinary income was ¥41.907 billion against ¥55.777 billion a year ago. Net income was ¥31.50 billion against ¥39.612 billion a year ago. Fully diluted net income per share was ¥57.51 against ¥72.32 a year ago. For the quarter, the company reported net sales of ¥94.5 billion against ¥88.5 billion a year ago. Operating income (prior to amortization of goodwill) was ¥12.2 billion against ¥12.6 billion a year ago. Operating income was ¥9.8 billion against ¥10.3 billion a year ago. Ordinary income was ¥5.7 billion against ¥10.2 billion a year ago. Income before income taxes and minority interests was ¥4.6 billion against ¥9.2 billion a year ago. Net income was ¥3.8 billion against ¥6.7 billion a year ago. EPS prior to amortization of goodwill of ¥11.28 against ¥16.57 a year ago. For the six months ending June 2015, the company expects net sales of ¥172 billion, operating income (prior to amortization of goodwill) of ¥21.1 billion, operating income of ¥16.5 billion. EPS prior to amortization of goodwill of ¥50.71. Capital expenditure of ¥12.8 billion. For the year of 2015, the company expects net sales of ¥354 billion, operating income (prior to amortization of goodwill) of ¥50.7 billion, operating income of ¥41.5 billion, ordinary income of ¥34 billion, income before income taxes and minority interests of ¥31.5 billion, net income of ¥18.5 billion. EPS of ¥33.8. Capital expenditure of ¥24.2 billion.

Kyowa Hakko Kirin Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending December 31, 2015

Kyowa Hakko Kirin Co., Ltd. provided dividend guidance for the fiscal year ending December 31, 2015. For the period, the company expects to pay interim dividend of JPY 12.50 per share and year end dividend of JPY 12.50 per share compared to interim dividend of JPY 12.50 per share and year end dividend of JPY 12.50 per share paid in the same period a year ago. Scheduled start date of dividend payment to be March 23, 2015.

Kyowa Hakko Kirin Co., Ltd., 2014 Earnings Call, Feb 02, 2015

Kyowa Hakko Kirin Co., Ltd., 2014 Earnings Call, Feb 02, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4151:JP ¥1,445.00 JPY +1.00

4151 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albemarle Corp $56.57 USD +0.27
Genmab A/S kr493.00 DKK -5.80
Insys Therapeutics Inc $60.06 USD -0.65
MorphoSys AG €74.66 EUR +0.153
Seattle Genetics Inc $36.25 USD -0.18
View Industry Companies
 

Industry Analysis

4151

Industry Average

Valuation 4151 Industry Range
Price/Earnings 49.9x
Price/Sales 2.4x
Price/Book 1.3x
Price/Cash Flow 21.7x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KYOWA HAKKO KIRIN CO LTD, please visit www.kyowa-kirin.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.